How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7 results for

Estrostep

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Estrostep

Estrostep Estrostep Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Estrostep Estrostep Aka: Estrostep II. Preparations (Norethindrone (...) Acetate / Ethinyl Estradiol) Estrostep (1 / 20 - 30 - 35) III. Components 1 mg (see preparation above) 20 ug - 30 ug - 35 ug IV. Effects Relative : 1.2 (high) : 16 (low) : 0.53 (high) V. Pill associated problems Indications to switch to (lower androgen) Indications to switch to Increased Appetite (lower ) provoked (lower ) Indications to switch to Break-through bleed days 1-9 (more ) Break-through bleed all of month (more ) too light (more , less ) Indications to switch to Libido decreased (more

2018 FP Notebook

2. Estrostep

Estrostep Estrostep Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Estrostep Estrostep Aka: Estrostep II. Preparations (Norethindrone (...) Acetate / Ethinyl Estradiol) Estrostep (1 / 20 - 30 - 35) III. Components 1 mg (see preparation above) 20 ug - 30 ug - 35 ug IV. Effects Relative : 1.2 (high) : 16 (low) : 0.53 (high) V. Pill associated problems Indications to switch to (lower androgen) Indications to switch to Increased Appetite (lower ) provoked (lower ) Indications to switch to Break-through bleed days 1-9 (more ) Break-through bleed all of month (more ) too light (more , less ) Indications to switch to Libido decreased (more

2015 FP Notebook

3. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. (PubMed)

Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. The Acne-Specific Quality of Life Questionnaire (Acne-QoL) is a responsive, reliable and valid instrument developed to measure the impact of facial acne across four dimensions of patient QOL. Score changes on this instrument have been used to report statistically significant treatment advantages for a low-dose oral contraceptive (Estrostep, containing norethisterone (norethindrone) acetate

2003 PharmacoEconomics

4. Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne

isotretinoin (i.e. Accutane) for 6 months Ortho Tri-Cyclen or Estrostep for 3 months Oral antibiotics (i.e. tetracyclines, erythromycin) for 4 weeks Systemic corticosteroids for 4 weeks Systemic non-steroidal anti-inflammatory drugs (NSAIDs) at anti-inflammatory doses for 4 weeks Topical (applied to skin) retinoid creams, ointments, gels for 2 weeks Topical antibiotics (i.e. tetracyclines, erythromycin, clindamycin) for 2 weeks Topical corticosteroids or topical non-steroidal anti-inflammatory (NSAIDs

2002 Clinical Trials

5. A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development. (PubMed)

follicles in healthy women who took Estrostep or Loestrin oral contraceptives (manufactured by Parke-Davis) or a placebo during three consecutive menstrual cycles.Sixty-three percent of placebo-treated subjects developed follicles greater than 18 mm, compared with 39% and 23% in the Estrostep and Loestrin groups. The risks for each group of developing a large follicle during a single cycle were not different. No dominant follicle persisted for greater than 2 weeks for any subject.These results

1992 American journal of obstetrics and gynecology

6. "Estrophasic" dosing: A new concept in oral contraceptive therapy. (PubMed)

"Estrophasic" dosing: A new concept in oral contraceptive therapy. The first of a new "estrophasic" type of oral contraceptive with 20 microg ethinyl estradiol on cycle days 1 through 5, 30 microg ethinyl estradiol on days 6 through 12, and 35 microg ethinyl estradiol on days 13 through 21 and 1 mg norethindrone acetate throughout the cycle (Estrostep; Parke-Davis, Morris Plains, NJ) combines a continuous low progestin dose with a low, gradually increasing estrogen dose. It was developed (...) to ensure good cycle control while conferring the benefits of low hormone content, such as minimizing estrogen-related side effects. In a double-blind, randomized, parallel-group trial, Estrostep provided acceptable cycle control and excellent tolerableness, comparable to that of the 30-microg ethinyl estradiol monophasic control drug. In a second study Estrostep demonstrated a neutral impact on serum lipids, like the triphasic control drug. This new oral contraceptive design offers a useful low-dose

1999 American journal of obstetrics and gynecology

7. A comparison of a new graduated estrogen formulation with three constant-dosed oral contraceptives. (PubMed)

product, Estrostep. A total of 1,850 cycles were completed and analyzed for efficacy, side effects, metabolic changes, and cycle control. Four pregnancies occurred during the course of the study. None of the pregnancies occurred in the group receiving Estrostep. The new formulation produced the lowest rate of breakthrough bleeding (BTB) compared with the other three products. All four combination oral contraceptives resulted in an increase in high-density lipoprotein cholesterol (HDL-C). The levels (...) of HDL-C were greatest with Estrostep.

1987 Contraception

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>